Thinking of joining a study?

Register your interest

NCT05250674 | COMPLETED | Contrast Enhanced Mammography-guided Biopsy


Clinical Evaluation of CEM-guided Biopsy
Sponsor:

Salut Mariage

Brief Summary:

CEM-guided biopsy is an optional accessory of Senographe Pristina intended to provide accurate location of lesions in the breast in three dimensions, using information obtained from Contrast Enhanced Mammography (CEM) images. This information provides guidance for a variety of minimally invasive or interventional procedures in the breast such as vacuum assisted biopsy, core biopsy, presurgical localization (e.g. hook wire), and fine needle aspirations (FNA). This device cannot be used for reasons other than its intended use. This evaluation is being done to learn more about the CEM-guided biopsy. Clinical user and operational feedback is a central part of the development process for medical devices in which information from real clinical use is required to optimize the device prior to commercial release.

Condition or disease

Contrast Enhanced Mammography-guided Biopsy

Intervention/treatment

CEM-guided biopsy

Detailed Description:

Pristina Serena CEM is an option to the standard Pristina Serena breast biopsy unit. It is designed to allow the accurate localization of lesions in the breast in three dimensions, using information obtained from Contrast Enhanced Mammography (CEM) images. It is intended to provide guidance for histological purposes such as core or vacuum-assisted biopsies, for pre-surgical localization procedures, or Fine Needle Aspiration (FNA) for cytopathology analysis. The main purpose of this evaluation is to collect feedback to assess image readability and look-and feel, usability, workflow and user preference information from physicians and technologists who use CEM-guided biopsy to perform minimally invasive interventional breast procedures under clinical conditions. All feedbacks are collected by observations, interviews and surveys. The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination, and considered eligible for this procedure as per standard of care. Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation.

Study Type : OBSERVATIONAL
Estimated Enrollment : 66 participants
Official Title : Clinical Evaluation of CEM-guided Biopsy
Actual Study Start Date : 2019-10-08
Estimated Primary Completion Date : 2021-09-27
Estimated Study Completion Date : 2021-10-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • * Adult women presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination, and considered eligible for this procedure as per standard of care.
  • * Are able and willing to comply with study procedures
  • * Are able and willing to provide written informed consent to participate
Exclusion Criteria
  • * Findings not accessible for stereotactic guidance biopsy
  • * Are currently lactating
  • * Have breast implants

Clinical Evaluation of CEM-guided Biopsy

Location Details

NCT05250674


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

Spain, Catalonia

Hospital del Mar - Parc de Salut Mar

Barcelona, Catalonia, Spain, 08003

Loading...